5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Treatment options for relapsed and refractory multiple myeloma.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over the last few decades, significant improvement in outcomes has been observed for myeloma patients, mainly as a result of the use of currently available approved antimyeloma agents, along with combining autologous stem cell transplantation in the treatment of myeloma. With more targeted agents in development, the treatment of a myeloma patient at relapse has become complicated and, as a consequence, results in vast heterogeneity in treatment patterns. Although a consensus on the timing of initiation of treatment, the choice of agents to be used, and the role of transplant is less clear, we describe an evidence-based approach and the factors to consider upon relapse. We describe additional newer agents and targets that are under development, with the goal of achievement of durable remissions for myeloma patients.

          Related collections

          Author and article information

          Journal
          Blood
          Blood
          1528-0020
          0006-4971
          May 14 2015
          : 125
          : 20
          Affiliations
          [1 ] Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; and.
          [2 ] Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
          Article
          blood-2014-11-568923
          10.1182/blood-2014-11-568923
          25838342
          5d279a60-1375-4f4e-a5f3-27d68825c3ea
          © 2015 by The American Society of Hematology.
          History

          Comments

          Comment on this article